Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer

被引：6

作者：

Ilhan, Yusuf ^{[1
]}

Tatli, Ali Murat ^{[1
]}

Teker, Fatih ^{[2
]}

Onder, Arif Hakan ^{[3
]}

Kose, Fatih ^{[4
]}

Geredeli, Caglayan ^{[5
]}

Karaagac, Mustafa ^{[6
]}

Kaplan, Muhammet Ali ^{[7
]}

Inanc, Mevlude ^{[8
]}

Aydin, Sabin Goktas ^{[9
]}

Kargi, Aysegul ^{[10
]}

Arak, Haci ^{[2
]}

Ozturk, Banu ^{[3
]}

Besen, Ali Ayberk ^{[4
]}

Selvi, Oguzhan ^{[5
]}

Korkmaz, Mustafa ^{[6
]}

Oruc, Zeynep ^{[7
]}

Bozkurt, Oktay ^{[8
]}

Bilici, Ahmet ^{[9
]}

Bayram, Selami ^{[3
]}

Dae, Shute Ailia ^{[4
]}

Ozdogan, Mustafa ^{[10
]}

Coskun, Hasan Senol ^{[1
]}

Goksu, Sema Sezgin ^{[1
]}

机构：

[1] Akdeniz Univ, Dept Med Oncol, Antalya, Turkey

[2] Gaziantep Univ, Dept Med Oncol, Gaziantep, Turkey

[3] Antalya Training & Res Hosp, Dept Med Oncol, Antalya, Turkey

[4] Baskent Univ, Dept Med Oncol, Adana Uygulama & Arastirma Merkezi, Adana, Turkey

[5] Okmeydani Training & Res Hosp, Dept Med Oncol, Istanbul, Turkey

[6] Necmettin Erbakan Univ, Dept Clin Oncol, Meram Fac Med, Konya, Turkey

[7] Dicle Univ, Dept Med Oncol, Diyarbakir, Turkey

[8] Erciyes Univ, Dept Med Oncol, Kayseri, Turkey

[9] Istanbul Medipol Univ, Dept Med Oncol, Istanbul, Turkey

[10] Medstar Antalya Hosp, Dept Med Oncol, Antalya, Turkey

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2022年 / 32卷 / 04期

关键词：

cervical cancer; SQUAMOUS-CELL CARCINOMA; PHASE-II; CHEMOTHERAPY; TRIAL;

D O I：

10.1136/ijgc-2021-003165

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objective Cisplatin-paclitaxel and bevacizumab is a frequently used treatment regimen for metastatic or recurrent cervical cancer, and carboplatin-paclitaxel and bevacizumab are also among the recommended regimens. In this study we aimed to evaluate the efficacy of these two regimens for the treatment of metastatic or recurrent cervical cancer. Methods Patients with metastatic or recurrent cervical cancer treated with cisplatin-paclitaxel and bevacizumab or carboplatin-paclitaxel and bevacizumab were retrospectively evaluated in this study. The clinical and demographic characteristics of patients in each group were evaluated. Median overall survival, progression-free survival, and response rates between the two groups were compared. Results A total of 250 patients were included. Overall, the numbers of patients with recurrent disease and metastatic disease were 159 and 91, respectively. The most common histologic subtype was squamous cell carcinoma (83.2%). The median duration of follow-up was 13.6 (range 0.5-86) months. The median progression-free survival was 10.5 (95% CI 9.0 to 11.8) months in the cisplatin-paclitaxel and bevacizumab group (group 1), and 10.8 (95% CI 8.6 to 13.0) months in the carboplatin-paclitaxel and bevacizumab group (group 2) (HR 1.20; 95% CI 0.88 to 1.63; p=0.25). The median overall survival was 19.1 (95% CI 13.0 to 25.1) months in group 1 and 18.3 (95% CI 15.3 to 21.3) months in group 2 (HR 1.28; 95% CI 0.91 to 1.80; p=0.15). Conclusions There is no survival difference between cisplatin or carboplatin combined with paclitaxel and bevacizumab in metastatic or recurrent cervical cancer.

引用

页码：502 / 507

页数：6

共 20 条

[1]

ARSENEAU J, 1986, INVEST NEW DRUG, V4, P187

[2]

Belani Chandra P, 2004, J Natl Compr Canc Netw, V2 Suppl 2, pS10

[3]

Cetina L, 2008, EUR J GYNAECOL ONCOL, V29, P608

[4] Cisplatin plus paclitaxel chemotherapy with or without bevacizumab in postmenopausal women with previously untreated advanced cervical cancer: a retrospective study [J].